ReviewCNS drugs2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Review in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 122 citations in OpenAlex.
- Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.Journal of neurology · 2025Trial
- Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.Neurology · 2024Trial
- Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.JAMA neurology · 2026Article
- Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.Neurology · 2026Article
- Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.Neurology and therapy · 2026Article
- Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.Neurology and therapy · 2026Article
- Baseline Neuroinflammation Stratifies TSPO-PET Response to Disease-Modifying Therapy in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Exit strategy patterns in second-line therapies for relapsing forms of multiple sclerosis.Acta neurologica Belgica · 2026Article
- Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.Journal of neurology · 2026Observational
- Long-Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real-World Longitudinal Study.Health science reports · 2026Article
- Psychiatric comorbidities in multiple sclerosis patients and their relationship with clinical variables: A university hospital sample.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2026Article
- Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?Neurology and therapy · 2026Article
- Antigen-Specific Inverse Vaccination Strategies Using Particle Systems for Multiple Sclerosis.ACS biomaterials science & engineering · 2026Review
- Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs.Therapeutic advances in neurological disorders · 2026Article
- Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis.Therapeutic advances in neurological disorders · 2026Article
- Epstein-Barr virus-associated multiple sclerosis: recent mechanistic advances and clinical therapeutic perspectives.Frontiers in immunology · 2026Review
- Natural flavonoids in multiple sclerosis: molecular insights and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Therapeutic biologics interference in serological and pre-transfusion testing.Frontiers in immunology · 2026Review
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.Therapeutic advances in neurological disorders · 2026Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensus guidelines offering differing recommendations, there is broad heterogeneity in how the DMTs are used in clinical practice. Choosing a DMT for newly diagnosed patients with MS is currently a topic of significant debate in MS care. Historically, an escalation approach to DMT was used for newly diagnosed patients with RRMS. However, the evidence for clinical benefits of early treatment with high-efficacy therapies (HETs) in this population is emerging. In this review, we provide an overview of the DMT options and MS treatment strategies, and discuss the clinical benefits of HETs (including ofatumumab, ocrelizumab, natalizumab, alemtuzumab, and cladribine) in the early stages of MS, along with safety concerns associated with these DMTs. By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.